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N o one would deny the human or moral imperative toprovide the best medical treatment for neonates
with hypoplastic left heart syndrome (HLHS). The
question, as usual, is how to define what is best. Before
1980, when no effective treatment was available, HLHS
was uniformly fatal within the first month of life.1,2 The
development of the Norwood procedure in 1980 and the
first application of cardiac transplantation in 1986 have
afforded new hope to the families of newborn infants
with this lethal heart defect.3-7 Although the reconstruc-
tive approach requires a sequence of technically diffi-
cult procedures associated with a high operative mor-
tality, actuarial 1-year and 5-year survivals of all treated
patients (including those at high risk) approach 70%
and 60% in experienced institutions.3,8 Actuarial 1-year
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(stage I: 106; stage II: 49; stage III: 25; 4 converted to heart transplantation).
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HYPOPLASTIC LEFT HEART SYNDROME: VALUING THE SURVIVAL
SURGERY FOR CONGENITAL HEART DISEASE
and 5-year survival curves for cardiac transplantation
in infants with HLHS are 84% and 76% in experienced
institutions.9,10 These survival figures, however, do not
include the mortality of children on the waiting list,
which according to the Pediatric Heart Transplantation
Study Group is around 31%.11
With these survival outcomes having been achieved,
the focus of inquiry has expanded to include a broader
set of issues. First, dimensions of health and well-being
beyond survival have become increasingly important.
Little is known, however, about the developmental sta-
tus or quality of life of children with HLHS.12,13 In fact,
our review of the literature disclosed only two articles
concerning neurologic development and no articles
concerning quality of life in patients with HLHS.
Second, as with all new interventions, particularly the
more dramatic and expensive approaches to saving
lives, there are pressures to assess both their benefits
and their costs. Here, too, little is known; our review of
the literature disclosed only two economic analy-
ses.14,15 This article, therefore, not only focuses on sur-
vival, but also examines the developmental status, qual-
ity-of-life, and cost outcomes associated with the
staged repair of HLHS at our institution.
Methods
The overall study population includes all patients (n = 106)
with HLHS and aortic atresia or near atresia who received
surgical intervention at Columbia-Presbyterian Medical
Center (CPMC) from February 1990 through March 1999. In
view of the severe shortage of donor organs and the compa-
rable survival outcomes of staged repairs and transplantation,
our institution follows a staged repair protocol for all children
who undergo surgery for the treatment of HLHS.
This study was initiated in January of 1998. All 106
patients were included in the analysis of survival. The out-
come measures of quality of life and developmental status
were obtained in a prospective fashion during the period
from January 1998 through March 1999. Because patients
were at various stages of surgical repair during this data col-
lection period, the study design is cross-sectional and
patients were not followed up longitudinally. The subgroup
(n = 51) in which we measured developmental status and
quality of life included all surviving patients older than 4
months of age for the Ages and Stages Questionnaire (ASQ)
and 2 months of age for the Infant/Toddler Child Health
Questionnaire (IT CHQ).
Our hospital financial information system underwent a fun-
damental change in 1993. The format of data collection was
so different that we could not combine the data from the two
time periods. The economic analysis, therefore, includes all
patients operated on from January 1993 to January 1999
(stage I, 73; stage II, 36; stage III, 13). The research protocol
was approved by the Institutional Review Board at CPMC.
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We obtained informed consent from all participants complet-
ing the quality-of-life and developmental status assessments.
Surgical interventions
The Norwood procedure. The Norwood procedure was per-
formed with deep hypothermia (18°C) and circulatory arrest.
Up to April 1995, a patch of pulmonary allograft was used to
reconstruct the native aorta to allow connection of the pul-
monary trunk. After April 1995, no patch was used to aug-
ment the native aorta. Instead, the aortic isthmus, including
the duct, was resected. The diminutive ascending aorta was
transected at its junction with the innominate artery and the
aortic arch was opened longitudinally. The descending aorta
was mobilized distally, and a direct connection was then per-
formed between the distal aortic arch and the descending
aorta posteriorly. The pulmonary trunk was anastomosed
directly to the reconstructed aorta. The ascending aorta, func-
tioning as the main coronary artery, was then anastomosed to
the right lateral sinus of the neoaorta. A modified Blalock-
Taussig shunt using a polytetrafluoroethylene graft* (3, 3.5,
or 4 mm) between the base of the innominate artery and the
right pulmonary artery was created in all patients. Three sur-
geons were operating at CPMC over the study period.
Surgeon 1 performed 88 of the Norwood I procedures, sur-
geon 2 performed 12, and surgeon 3 performed 6 procedures.
Further procedures. Stage II procedures were either a bidi-
rectional Glenn operation or a hemi-Fontan operation. In the
majority of patients, enlargement of a central pulmonary
artery stenosis (at the site of the previous duct) was per-
formed during the same operation. The third stage of the
repair completed the Fontan circulation by means of an intra-
atrial polytetrafluoroethylene tunnel.
Developmental assessment 
The ASQ (for children 4 to 48 months). The ASQ is
designed to be completed by the infant or child’s parent or
primary caregiver. We analyzed 30 questions focusing on the
infant or child’s developmental repertoire. The 30 questions
are equally divided into 5 domains: communication skills,
gross motor function, fine motor function, problem solving,
and personal-social skills. Questions relate to the child’s abil-
ity to accomplish daily tasks, such as drawing circles, lining
up blocks, and throwing balls. A questionnaire appropriate
for the child’s age can be administered at the following inter-
vals: 4, 6, 8, 12, 16, 18, 20, 24, 30, 36, and 48 months of age.
Investigators administered the instruments between
January 1998 and March 1999. Nine patients were inter-
viewed after stage I, 10 patients after stage II, and 8 after
stage III during this time period. Scores for each domain are
compared with established norms. The normative ranges have
been established in a reference population and vary by
domain and age interval.16
The ASQ was designed as a screening instrument to iden-
tify those children who need extensive neurologic evaluation.
The simplicity of its design facilitates the administration both
*Gore-Tex graft, registered trade name of W. L. Gore & Associates,
Inc, Flagstaff, Ariz.
in person and by telephone and thus accommodates popula-
tion studies. Its limitation is that it does not provide an in-
depth picture of the neurologic deficits of the child, as would
be provided by a trained neurologist. Nonetheless, it provides
a “first cut” identification of those patients who are probably
developmentally impaired. Rather than a multiple-day battery
of neurologic testing, which would involve considerable time
commitment of patients and their parents, we chose for ease
of administration.17,18 The ASQ has been administered and
validated in a variety of health and primary care settings,
including children with heart defects and premature babies
who spent their first days in the neonatal intensive care unit.19
Quality-of-life assessment. Quality-of-life assessment in
children is notoriously difficult. Key aspects of quality of life,
such as physical, emotional, and social functioning, rapidly
evolve as the child ages.20,21 As a result, there is a need for
age-adjusted normative values, which allow children with
severe cardiac disease to be compared with healthy children
of the same age. Moreover, in the case of young children, par-
ents or primary caregivers need to be used as a proxy for
direct patient-based responses. Despite these difficulties, a
limited number of pediatric quality-of-life measures are cur-
rently being developed.22 To date, these measures have not
yet been used in HLHS or validated in children with severe
cardiovascular disease. We selected the Infant/Toddler Child
Health Questionnaire (IT CHQ) and the Child Health
Questionnaire PF-28 (CHQ PF-28). Despite the absence of
validation in seriously ill children with cardiovascular dis-
ease, this instrument is easy to administer and has been used
extensively in healthy populations and chronically ill
patients. Parents provided information on the quality of life of
their children by completing either the IT CHQ or the CHQ
PF-28, depending on the child’s age.
IT CHQ (for children between 2 months and 5 years). We
analyzed the following 9 domains of the IT CHQ: physical
abilities, growth and development, discomfort and bodily
pain, temperament and moods, general behavior, behavioral
interactions, general health perceptions, parental impact for
emotion, and parental impact for time. The latter two items
assess the health and well-being of the parent or family care-
giver, such as their mental health, global health, the amount
of anxiety or worry experienced, and limitations in time to
meet personal needs. Each of the domains is uniformly scored
on a 0 to 100 scale by the investigators, with 0 being the low-
est and 100 the highest achievable scores. Nine patients were
interviewed after stage I, 10 patients after stage II, and 8
patients after stage III between January 1998 and March
1999. The present study is the first application of this instru-
ment to critically ill children, including those with life-threat-
ening heart disease. Prior validation was conducted in a pop-
ulation of healthy children and children with otitis media
(personal communication with Jeanne Landgraf). The results
of this study will be used to further validate this instrument.
CHQ PF-28 (for children aged 5 years and older). The
CHQ PF-28 addresses 14 health concepts (physical function-
ing, role/social-physical, general health perceptions, bodily
pain, parental impact—time, parental impact—emotional,
role/social emotional, role/social behavioral, self-esteem,
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mental health, general behavior, family activities, family
cohesion, and change in health) and provides a summary mea-
sure for the 2 broad domains of physical and psychosocial
functioning. Each of the components is uniformly scored on a
0 to 100 scale. The CHQ has been extensively validated.20
For both the ASQ and quality-of-life scales (CHQ and IT
CHQ), a trained interviewer completed the questionnaire
with the parent or caregiver. After stage III, quality of life was
measured either by the IT CHQ or the CHQ dependent on the
age of the child.
Cost measurement. Measuring health care costs is fraught
with practical and conceptual difficulties. Although analyses
have historically used the charges that providers bill as prox-
ies for the costs of resources, charges may differ substantial-
ly from the resource costs of delivering care. In contrast to
charges, payments relate to actual financial transactions, but
these fixed reimbursements do not specify the actual amount
of resources used among the various hospital services.
Resource costs, the actual expenses paid to obtain the
resources used to deliver care, are the most desirable concep-
tually, but standard methods are still under development. The
ratio-of-cost-to-charges (RCC) method comes closest to
approximating actual resource costs. This RCC is calculated
by each hospital in the following manner: at the end of the
year, a hospital compares its actual expenditures (costs) per
resource category (eg, operating room, diagnostic tests, or
bed days) to its charges.23 The hospital develops an RCC for
each resource category to reflect these actual expenditures. In
light of this, we use the RCC method as the primary approach
for measuring hospital cost, and we use payments for other
providers’ expenses. We have taken the “health care budget”
perspective in this analysis, calculating the direct costs of all
medical services associated with providing health care to
patients with HLHS who are managed surgically, regardless
of who bears the cost. This excludes the direct costs borne out
of pocket by the families (such as travel and loss of produc-
tivity because of caretaking time). Indirect costs (ie, loss of
productivity of patients) are not germane to this pediatric
population.
We audited the hospital patient management system and
gathered the line-item bills for hospital services and supplies
for all patients with HLHS being analyzed. For each patient
we captured the billable item, the date of the charge, and the
amount of the charge. Inpatient routine charges included both
intensive care unit and regular floor days. For ancillary ser-
vices billed, each item was categorized into a departmental
category (eg, chemistry, radiology) and each department cat-
egory was then further categorized into use categories (eg,
diagnostic tests). These categories included operating room,
diagnostics, laboratory, blood products, drugs, therapeutic
procedures, and rehabilitation. For each patient, we summed
the total charges in each departmental category that were
incurred in the period ranging from the day of hospitalization
to the discharge date. For each departmental category, we
multiplied the total charges by the corresponding RCC sub-
mitted by CPMC in its Health Care Financing Administration
yearly institutional cost report. Another important component
of the cost (to society) of initial hospitalization is the cost of
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the time spent and services provided by physicians. The dif-
ficulty with assessing such costs is that professional charges
do not necessarily correspond to the actual cost of the ser-
vices. The best solution to this problem is to report the actu-
al financial expenditure: the payments made by third-party
health care payers. Thus the actual dollars spent are captured.
We used the departmental financial reimbursement records to
account for all payments made to physicians, including car-
diothoracic surgeons, anesthesiologists, cardiologists, and
neonatologists.
Outpatient services include physician care, diagnostic tests,
and medications related to cardiovascular care performed at
CPMC; we imputed the number of physician visits, diagnos-
tic tests, and use of out-of-hospital medications from a stan-
dard outpatient protocol used in our institution. We valued the
costs of physicians’ services by examining the reimburse-
ments they received. All diagnostic tests were performed in
the hospital and the associated charges were, again, convert-
ed to costs using hospital RCCs. We imputed the number of
outpatient physician visits from the outpatient protocol.
Outpatient diagnostic tests came from the clinical informa-
tion system. Use of out-of-hospital medications was derived
from outpatient medical records. Outpatient medications
were based on the average wholesale price for each drug list-
ed in the Drug Topics Red Book.24 We identified all readmis-
sions from the clinical information system and used the RCC
method to assess their cost.
Baseline factors analyzed. The following potential predic-
tors of outcome were considered: severely obstructed atrial
septal defect, age at stage I operation, sex, gestational age,
prematurity (<35 weeks), low birth weight (<2.5 kg), chro-
mosomal abnormalities, Apgar score, preoperative ventilato-
ry support, preoperative cardiac support with inotropic drugs
(excluding dopamine, 2 µg · kg–1 · min, for renal perfusion),
surgeon, circulatory arrest time, and major extracardiac
abnormalities.
Statistical analysis. The survival data were first examined
univariately by means of standard contingency tables and the
Kaplan-Meier product-limit estimate. Any variable with a P
value less than .25 was explored as a potential risk factor in a
multivariable analysis. The Cox proportional hazards model
was used for the multivariable survival analysis of time to
death. Time zero was the date of the Norwood stage I repair.
Four patients undergoing transplantation were censored at the
date of transplantation. The model was checked for correla-
tions to prevent multiple collinearity. The proportional haz-
ards assumption was satisfied. We calculated the relative risk
of death along with 95% confidence intervals (CIs).
Quality-of-life data were analyzed by the nonparametric
analog to the analysis of variance (Kruskal-Wallis test) for
the CHQ, and ASQ data were analyzed by the Fisher exact
test for dichotomous outcomes. For the IT CHQ, we used the
Dunnett multiple comparison procedure to compare group
means to the reference populations. Because raw data were
not available for the reference populations, we used an algo-
rithm to compare the group means by calculating the test sta-
tistic Li.25 To determine significance, we then compared these
values to a table of critical values for the Dunnett criterion
using an independently estimated variance (see appendix).26
A multiple, linear regression analysis was performed to
examine which risk factors determined costs. All data were
analyzed with SAS system software (SAS, Inc, Cary, NC).
The results of all statistical analyses are presented without
correction for multiple testing.
Results
Patient population. One hundred one of the 106
patients had classic HLHS, with aortic atresia in 91
patients and echocardiographic evidence of some ante-
grade flow from a diminutive left ventricle into the
hypoplastic ascending aorta in 10 patients. In 5
patients, the ventricular anatomy was more complex.
Two of these patients had aortic atresia, and ventricular
contribution to antegrade flow in the ascending aorta
was minimal in the other 3 patients. Patients undergo-
ing the Norwood procedure for lesions with HLHS but
with more significant antegrade ascending aortic flow
were excluded from this study.
The median age at stage I surgery was 6 days (range
0-57 days), and the median weight was 3252 g (range
1160-3330 g). Seventy-two patients (68%) were boys
and 34 (32%) were girls. The median age for the stage
Fig 1. Flow chart.
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II procedure was 9 months (range 6-18 months).
Completion of the Fontan (stage III) circulation was
undertaken at a median age of 34 months (range 1.5-
5.9 years).
Survival. Fig 1 depicts the flow of patients through
the staged repair process. One hundred six patients
underwent the stage I Norwood procedure. The median
circulatory arrest time was 51 minutes (25th percentile,
45 minutes; 75th percentile, 60 minutes). Seventy-two
children (68%) survived the hospitalization. Four
patients required conversion to cardiac transplantation,
with 1 early postoperative death, and 12 patients are
presently alive and await a stage II procedure. Forty-
nine patients underwent stage II repair (bidirectional
Glenn operation, 45 patients; hemi-Fontan operation, 4
patients). There were 2 early postoperative deaths, and
47 patients (96%) were discharged from the hospital.
Of this group, 21 patients await a stage III procedure
and 26 children underwent stage III repair with 1 early
postoperative death (96% survived hospitalization).
Fig 2 contains a Kaplan-Meier plot of overall sur-
vival for the entire group of 106 patients (the 4 heart
transplant recipients were censored at the point of
transplantation). The 1-year, 2-year, and 5-year sur-
vivals were 58% (95% CI: 48.4%, 67.8%), 57% (95%
CI: 47.1%, 66.5%), and 54% (95% CI: 43.9%, 64.8%),
respectively. Nearly all of the deaths (94%) occurred
before the second stage of the repair. The 1-year sur-
vival after stage II repair was 94% (95% CI: 85.0%,
100%), and the 1-year survival after stage III repair was
96% (95% CI: 88.8%, 100%).
The multivariable model found significance for sev-
eral factors (Table I). For every 500-g decrease in
birth weight, the relative risk of dying was 1.35. The
need for preoperative pressors increased the risk of
dying by 2.5. Patients treated by surgeons 2 and 3 had
Fig 2. Survival curve of the entire cohort (n = 106). The squares represent actual events, positioned along the hor-
izontal axis at the time of the event and by the Kaplan-Meier method along the vertical axis. The vertical bars
represent 95% confidence intervals. Numbers in parentheses represent patients remaining.
Table I. Cox proportional hazards model
Variable Parameter estimate SE P > (χ2) Risk ratio Lower 95% CL* Upper 95% CL
Surgeon* 1.609965 0.34513 .0001 5.003 2.543 9.839
Weight –0.000597 0.0002301 .0095 1.348† 1.076 1.689
Dopamine 0.898473 0.31278 .004 2.456 1.33 4.534
SE, Standard error; CL, confidence limit.
*Operating surgeon was other than surgeon number 1.
†For each 500-g decrease in birth weight.
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an increased mortality (relative risk: 3.9; 95% CI: 1.9,
7.8; Fig 3). The 1-year, 2-year, and 5-year survivals of
patients operated on by the high-volume surgeon were
66% (95% CI: 55.7%, 75.8%), 64% (95% CI: 53.4%,
74.4%), and 60% (95% CI: 48.7%, 72.3%), respec-
tively.
Developmental status. Twenty-seven of the 37 eligi-
ble parents (73%) completed the ASQ for their children.
We were unable to locate 6 families, 2 families did not
speak English, and 2 declined participation. Table II
depicts the results of the ASQ testing by surgical stage.
The first 5 rows show the percentage of patients without
delayed development for the specified domain, and the
6th row shows the percentage of patients without any
developmental delay in any domain. The last column
shows the P values for the results in early (I) and late-
stage (II and III) repair; the group of patients with stage
I repair had more developmental delays than the groups
having stage II or III repair. None of the potential pre-
dictive factors correlated with developmental status,
except circulatory arrest. Patients with higher circulato-
ry arrest times are less likely to achieve normal prob-
lem-solving scores (P < .06).
Quality of life 
IT CHQ. The ASQ and the IT CHQ are administered
together. Seventy-three percent of parents completed
the IT CHQ, and the reasons for noncompletion were
the same as mentioned earlier. Table III depicts the
scores for the various domains, as well as the mean and
standard deviation for a healthy population of children
from Australia.22 After stage I repair, HLHS children
were not significantly different from the normal popu-
lation. After stage II, however, HLHS children scored
significantly worse on physical ability scale, on growth
and development, on discomfort and pain, on tempera-
ment and mood scale, on the general health perception
Fig 3.  Survival curve stratified by surgeon. The squares and triangles represent actual events, positioned along
the horizontal axis at the time of the event and by the Kaplan-Meier method along the vertical axis. The vertical
bars represent 95% confidence intervals. Numbers in parentheses represent patients remaining.
Table II. Ages and Stages Questionnaire (ASQ)
Fisher exact test 
Domain Stage I (n = 9) Stage II (n = 10) Stage III (n = 8) (stage I vs II and III)
Communication 44% 80% 88% P = .07
Gross motor 44% 30% 75% P = 1.0
Fine motor 56% 60% 88% P = .4
Problem solving 67% 70% 63% P = 1.0
Personal and social 67% 80% 88% P = .2
Meeting benchmarks in all domains 0% 40% 50% P = .06
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scale, and on the emotional parental impact scale. After
stage III, HLHS patients were significantly better on
the discomfort and pain scale than the reference popu-
lation. They were significantly worse on only 1 scale:
the general health perception scale. For all other scales,
there was no significant difference from the reference
population.
We correlated each of the baseline factors with the
domains and found no single factor, or combination
of factors, predictive of the outcomes in each of these
domains except circulatory arrest time. Patients with
lower circulatory arrest time (≤40 minutes) per-
formed significantly better in the following domains:
growth and development (P < .02), discomfort and
pain (P < .01), temperament and moods (P < .03),
and behavior overall (P < .05).
CHQ. Eleven of the 14 eligible parents (79%) com-
pleted the CHQ. The children of all of these parents
had completed the HLHS staged repair process. We
were unable to locate 3 families. Table IV shows the
scores for the various domains and 2 summary scores.
The mean observed physical summary measure score
was 48.5 ± 6.3 and the mean observed psychosocial
summary measure score was 42.8 ± 9.9. When com-
pared with a normal population of 598 children aged 5
to 7 years* from Australia,20 HLHS patients scored sig-
nificantly lower in the following subscales: (1)
role/social limitations due to emotional or behavioral
difficulty; (2) behavioral; (3) self-esteem; (4) global
health item; (5) parental impact—emotional; (6) fami-
ly activities; and (7) psychosocial summary score.
However, on the following subscales HLHS patients
did not score significantly differently from the normal
reference population: (1) physical function; (2)
role/social limitations due to physical health; (3) bodi-
ly pain; (4) mental health; (5) parental impact—time;
Table III. Infant/Toddler Childhood Health Questionnaire (IT CHQ)
Age (y) PA GD BP TM GB BE GH PE PT
Stage I
Mean (n = 8) 0.8 92.1 92.2 82.3 81.1 82.9 73.3 47.5 80.4 86.9
SD 0.5 7.5 6.7 12.9 8.6 15.8 10.8 13.8 11.9 18.3
Stage II
Mean (n = 11) 1.9 75.5† 76.8† 62.9† 69.8† 77.2 68.5 42.0† 78.9† 77.9
SD 1.0 22.9 17.1 21.5 14.5 16.5 10.5 16.1 15.1 28.5
Stage III
Mean (n = 8) 3.8 90.4 80.6 85.4‡ 80.4 76.3 73.3 54.2† 83.0 85.7
SD 1.0 10.9 16.1 20.3 13.6 16.1 11.2 24.5 18.8 19.6
Normal*
Mean (n = 958) 98.3 93.2 79.1 82.0 74.5 79.0 76.7 91.8 93.2
SD 28.9 16.4 5.0 12.2 12.0 14.6 8.5 12.6 18.6
PA, Physical abilities scale; GD, growth and development item; BP, discomfort and pain scale; TM, temperament and moods scale; GB, behavior overall scale; BE,
getting along with others scale; GH, general health perceptions scale; PE, parental impact—emotional scale; PT, parental impact—time scale. 
*Based on a normal population (see text).
†Significantly lower than the reference normal population. 
‡Significantly higher than reference normal population.
Table IV. Childhood Health Questionnaire (CHQ)
Age (y) PF RP REB* BP BE* MH SE* GH* PE* PT FA* FC PHS PSS*
HLHS (n = 11)
Mean 7.3 85.9 93.9 66.7 90.9 59.3 72.0 74.2 42.6 63.6 78.8 64.8 64.1 48.5 42.8
SD 0.9 19.9 20.1 29.8 10.4 19.7 16.8 14.7 19.1 18.1 15.1 30.0 16.1 6.3 9.9
Normal population† (n = 83)
5-7
Mean 96.7 93.2 94.5 84.4 71.5 80.3 87.3 96.3 81.2 88.8 89.2 76.9 53.7 52.1
SD 16.7 22.2 17.6 16.7 14.9 15.1 13.7 21.4 1.9 20.2 22.2 21.4 10.9 7.9
PF, Physical functioning scale; RP, role/social limitations due to physical health scale; REB, role/social limitations due to emotional or behavioral difficulty scale;
BP, bodily pain scale; BE, behavior scale; MH, mental health scale; SE, self-esteem scale; GH, global health item scale; PE, parental impact—emotional scale; PT,
parental impact—time scale; FA, family activities scale; FC, family cohesion item; PHS, physical summary score; PSS, psychosocial summary score. 
*Subscales in which HLHS cohort differed significantly from normal population (P < .05).
†Based on a normal population (see text).
*This reference population was, on average, slightly younger than our
study group but was the closest group in age for which data were
available.
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(6) family cohesion item; and (7) physical summary
score.
Gestational age (P < .01, R2 = 0.8690) and circulato-
ry arrest time (P < .01) were predictive of the physical
health summary score, with the former being positive-
ly correlated and the latter being negatively correlated.
Neither gestational age nor circulatory arrest time cor-
related with the psychosocial summary score.
Cost. The median cost of the initial stage I–related
hospitalization was $51,100 (25th percentile, $41,044;
75th percentile, $70,374). The median costs of the hos-
pitalizations for stage II and III repairs were $33,892
(25th percentile, $24,527; 75th percentile, $52,943)
and $52,183 (25th percentile, $47,781; 75th percentile,
$69,836), respectively. The cost breakdown by resource
use categories is depicted in Table V.
Moving beyond hospitalization for the staged proce-
dures, we examined outpatient costs and readmissions
(Table VI). There were a total of 51 readmissions for 29
patients who had completed stage I repair, 15 readmis-
sions for 12 patients who had completed stage II repair,
and 4 readmissions for 1 patient after the stage III pro-
cedure (see Table VII for the breakdown of reasons for
readmission). The median monthly outpatient and read-
mission cost of treating an HLHS patient was $927
after stage I, $224 after stage II, and $255 after stage
III. Baseline factors did not correlate with total costs.
Discussion
This article has begun to explore the more compre-
hensive outcomes of the staged repair approach for
HLHS in our institution. The vast majority of these
Table V. Hospitalization costs for entire cohort
Stage I procedure Stage II procedure Stage III procedure
Median (25th percentile, Median (25th percentile, Median (25th percentile,
Resource category 75th percentile) (n = 73) 75th percentile) (n = 36) 75th percentile) (n = 13)
Inpatient bed days $18,550 (9,275, 31,521) $13,086 ($8,536, $18,113) $15,232 ($12,482, $20,720)
Operating room $10,149 ($9,031, $15,715) $7,170 ($2,834, $16,359) $14,000 ($8,843, $2,659)
Diagnostics $2,864 ($1,520, $3,887) $1,098 ($827, $2,418) $1,345 ($924, $2,825)
Laboratory $2,055 ($1,477, $3,183) $1,059 ($715, $1,830) $1,384 ($951, $2,637)
Blood products $802 ($712, $1,072) $382 ($244, $728) $264 ($256, $946)
Drugs and supplies $4,310 ($1,002, $10,263) $743 ($234, $1,267) $1,603 ($406, $2,938)
Rehabilitation $750 ($12, $1,614) $202 ($0, $699) $28 ($0, $802)
Emergency department $0 ($0, $0) $0 ($0, $0) $0 ($0, $0)
Professional payments $5,063 ($3,050, $12,015) $6,711 ($875, $13,782) $17,147 ($4,442, $23,050)
Cost per patient $51,100 ($41,044, $70,374) $33,892 ($24,527, $52,943) $52,183 ($47,781, $69,836)
Table VI. Outpatient and readmission costs for entire cohort
Stage I procedure Stage II procedure Stage III procedure
No. of readmissions 51 (29 patients) 15 (12 patients) 4 (1 patients)
Median cost of readmissions per month $38 $24 $63
25th and 75th percentiles $19, $41 $19, $30 $25, $42
Monthly professional payments $155 $27 $38
(per protocol)
Monthly cost laboratory tests $794 $173 $175
and drugs (per protocol)
Median cost per patient per month $927 $224 $255
(25th and 75% percentiles) ($908, $930) ($219, $300) ($238, $276)
Table VII. Readmissions by cause
Reason for readmission Total No. = 70
Diagnostic catheterization 43
Upper respiratory tract infection 9
Viral syndrome 9
Pneumococcal septicemia 1
Pneumococcal pneumonia 1
Staphylococcal pneumonia/streptococcal septicemia 1
Urinary tract infection 1
Acute pericarditis 1
Pleural effusion 1
Hypovolemia 1
Gastritis with hemorrhage 1
Circumcision 1
patients had the extreme form of HLHS with aortic
atresia. Despite the prevalence of this anatomic char-
acteristic, our institutional l-year and 5-year survivals
were 58% and 54%. These levels are comparable
with those of other centers that are dedicated to the
staged repair of HLHS8 and are equivalent to expec-
tations for cardiac transplantation given the scarcity
of donor hearts. A further analysis of our survival by
means of multivariable techniques delineated a few
preoperative factors, including birth weight, surgical
experience, and hemodynamic instability, which had
a strong correlation with survival. Although much
remains to be learned about the treatment of HLHS
from rigorous survival studies, the primary focus for
this article is to begin characterizing the quality of
life and developmental progress achieved by patients
undergoing the staged repair. As such, we present our
survival experience to offer a context for interpreting
the other outcomes.
Developmental status, as measured by the ASQ, was
substantially delayed in our cohort. None of the
patients assessed after stage I surgery met all of the
benchmarks that are characteristic of normal develop-
ment. Communication and gross motor skills were the
areas in which fewest patients met the cutoffs for nor-
mal development. However, in this cross-sectional
study, 40% of patients having completed stage II and
50% of patients having completed stage III showed
normal developmental status on the ASQ.
There are, as mentioned, very few studies on neu-
rodevelopmental status in HLHS patients, and these
studies use different instruments, a fact which does
not facilitate making comparisons. With that caveat in
mind, we reviewed the literature on neurodevelop-
ment in patients with HLHS in the context of our
patients. Reporting on 7 patients after stage III
surgery or modified Fontan repair, Rogers and col-
leagues12 noted that the cognitive scores of 6 patients
were in the mental retardation range (3 severely to
profoundly retarded and 3 moderately retarded),
based on a battery of cognitive assessment instru-
ments (Clinical Adaptive Test–Clinical Linguistic
Auditory Milestone Scale, Bayley Scales of Infant
Development, and McCarthy Scales of Children’s
Abilities). Keeping in mind the differences in evalua-
tive procedures, the cognitive development that we
observed after stage III surgery was only moderately
impaired. Communication norms were achieved in
88% of the 8 patients who completed stage III, and
problem solving norms were completed in 63%. In
our study, circulatory arrest times correlated negative-
ly with problem-solving scores. This result corrobo-
rates earlier findings from this institution that pro-
longed circulatory arrest correlates negatively with IQ
scores.13 Rogers and associates12 found delayed
motor function development in 3 of 7 patients, and 2
others had cerebral palsy. By comparison, we
observed normal gross motor function in 75% of our
patients after stage III and normal fine motor function
in 88%. It is important to keep in mind that delays in
developmental status in these very young children,
who have not yet celebrated their 4th birthday, do not
mean that they will not catch up to their peers over
time. On the other hand, more subtle developmental
delays may appear over time. These outstanding ques-
tions make the case for the need for long-term analy-
sis of neurologic development.
Delayed developmental status does not necessarily
indicate poor quality of life. For the younger HLHS
children, parents’ perception of quality of life after
stage I was not significantly different from that in a ref-
erence population. This perception may reflect the
modest expectation held by most parents for children in
the first year of life. After stage II, however, HLHS
children scored significantly lower in several domains
than the reference population. These included their
physical ability, growth and development, discomfort
and pain, temperament and mood, general health per-
ception, and impact on parents’ emotions. After stage
III, by contrast, only general health perceptions were
significantly lower than those of the reference popula-
tion, and patients did better on the discomfort and pain
scale than the reference population. In general, it
appears that quality of life of children after stage III
repair is better than the quality of life of children after
stage II repair.
Quality of life in older children, as measured by their
summary psychosocial score, lags behind that of the
reference population of healthy children. However,
their physical summary score is not significantly dif-
ferent from that of the reference population. As was the
case for younger children, circulatory arrest time was a
factor in their quality of life.
This article provides a comprehensive look at the
economics of the staged repair process. The median
cost per patient of all 3 staged repair hospitalizations
is $137,175. This constitutes more than 90% of all the
direct medical costs of caring for these patients (ie,
readmissions and outpatient services and drugs
amount to 8% of the costs of care for these patients).
It is tempting to compare this figure with that of car-
diac transplantation. Our review of the literature dis-
closed 2 economic analyses. One study, using the dis-
charge database of the University Hospital
Consortium, compared hospital charges of the
Norwood procedure versus cardiac transplantation. In
728 Williams et al The Journal of Thoracic and
Cardiovascular Surgery
April 2000
636 patients admitted to 40 institutions between 1989
and 1993, median charges were $57,418 for the
Norwood procedure and $126,695 for transplanta-
tion.27 Another study compared selected hospital,
physician, and outpatient charges between the Fontan
operation and cardiac transplantation.28 The total
charges (surgery plus yearly follow-up) for the Fontan
procedure were $29,730 compared with $96,475 for
cardiac transplantation (P < .001 ).
These studies did not address actual resource use
because they used charges, which may differ substan-
tially from the actual costs of medical services.
Moreover, these studies do not provide a comprehen-
sive look at the costs of all stages of the reconstructive
process. At the same time, the assessment of transplan-
tation costs in these comparisons seriously underesti-
mates the costs associated with long-term immunosup-
pression, rehospitalizations, and diagnostic testing.
Moreover, these studies typically do not include the
cost of caring for children who are being supported
while awaiting transplantation, which would include
temporizing procedures.
In summary, the lack of long-term data on survival,
developmental status, quality of life, and costs has
greatly contributed to the controversy and uncertainty
regarding optimal treatment strategies. This article
offers a “first cut” estimate of the quality of life and
true costs associated with the staged repair of HLHS.
Our findings corroborate that these patients have devel-
opmental setbacks that may be related in part to circu-
latory compromise during the procedures. In the area of
quality of life, our patients achieve levels that are below
standard normal populations, but the group of patients
after stage III repair appears to be doing better than the
group after stage II. Although expensive, the total cost
of the staged repair is easily within the range of proce-
dures currently funded by industrialized nations for
life-threatening conditions. We believe that if the com-
prehensive approach to cost assessment taken here is
used to cost cardiac transplantation, the total cost of
transplantation will be considerably higher than that of
staged repair.
At the same time, the research methods used here
have limitations. We collected quality-of-life data dur-
ing a 14-month period and were not able to interview
the same patient at different stages of treatment. Thus
we do not have a longitudinal data set to adequately
explore time trends. Moreover, the small size of the
resulting data set restricts more in-depth statistical
analysis. Second, due to the absence of well-validated
instruments for measuring quality of life in younger
pediatric patients, we opted to use a quality-of-life
questionnaire that had never been tested in a critically
ill patient population. Our study data will be used by
the developer of the CHQ to validate its use in critical-
ly ill patients. Third, we captured the direct medical
costs associated with treatment but did not look at the
direct medical costs borne out of pocket by the families
of these patients (specifically, the time out of work due
to caregiving). Ultimately, if we want to capture the full
economic burden of cardiac disease on society, these
costs should be included.
What do the results of our study suggest for further
research in this area? There needs to be a prospective,
large-scale, possibly multicenter study of the compre-
hensive outcomes of staged repair and transplantation.
This study will need to address the longer-term devel-
opmental and quality-of-life outcomes, as well as the
long-term cost-effectiveness of these procedures.
Insights into these dimensions of health and economic
outcomes will be critical for all decision-makers facing
the choice of how to treat a given patient with HLHS.
We thank the following individuals for their help in gather-
ing the data for our analysis: Raymond Arons, Bala, Angela
Billet, Dina Brunstein, Robert Kroslowitz, Sharon Levine,
Beth Meyers, Dorothy Pearlman, and Vadim Potievski.
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Discussion
Dr John L. Myers (Hershey, Pa). The authors have taken on
a monumental task, to tease out the developmental outcome,
quality of life, and hospital costs in this group of patients. We
are all aware of the basic principles of the Norwood operation,
and all of us would believe that a perfect repair will result in a
good outcome. However, seemingly minor technical problems
can result in serious problems that may present themselves
acutely in the operating room, during the postoperative course,
or later in follow-up. Neurologic injury and residual cardiovas-
cular pathophysiology can result in developmental abnormali-
ties and a decrease in the quality of life. The etiology of this
neurologic morbidity is multifactorial and includes preopera-
tive, intraoperative, and postoperative issues. 
As has previously been stated, HLHS is an incurable form
of congenital heart disease. Until Norwood’s contribution
nearly 20 years ago, this defect was uniformly fatal. All
things considered, most programs with a dedicated interest in
neonatal congenital heart surgery have achieved success with
the Norwood operation. Many of us have cared for children
who have received the Norwood-Fontan palliation protocol
and are now entering their second decade, attending school,
participating in activities, and enjoying life. There are cer-
tainly many children with other forms of serious congenital
heart disease who are less fortunate in terms of their quality
of life. Despite the abnormalities and developmental status
that the authors are reporting, I believe that we are achieving
good results, but we still have room for improvement. 
My first question relates to developmental outcome. Have
you applied your developmental outcome analysis and quali-
ty-of-life assessment studies in other children with other
types of congenital heart disease? 
Also, since other groups have reported that socioeconomic
status seems to make a difference in developmental outcome,
could you describe the socioeconomic mix of your patient
group? 
Your developmental assessments were performed in 23 of
37 eligible patients; however, 46 patients are alive. Thus only
half of the survivors were actually assessed for developmen-
tal status. How might this affect the validity of your results? 
You identified 4 risk factors—low-volume surgeon, preop-
erative pressors, nonwhite race, and low birth weight—as risk
factors for survival. I can understand all of them except non-
white race. Do you have an explanation for that? 
My final comment and question relate to the summaries of
the hospitalization costs that are shown in Tables V and VI.
Approximately $175,000 is the cost for hospitalization for the
entire group averaged per patient. For those patients who are
alive after all 3 procedures, the average cost is $140,000.
Therefore, the obvious way to reduce cost and improve sur-
vival is to reduce morbidity and develop strategies to reduce
length of stay, particularly intensive care unit and hospital
stay, as you have pointed out. In your detailed analysis of this
group of patients and their hospital course, could you specu-
late on how you might reduce morbidity, mortality, and par-
ticularly hospital cost? 
Dr Quaegebeur. This is an excellent question and points
out one of the limitations in the study. These tests are screen-
ing tests; they are not extensive clinical tests. We have had
previous experience using clinical assessment of patients, and
it was very hard to get the cooperation from the patients. This
is a first attempt. These tests are used by a trained interview-
er with the parents. They have been used in critically ill
patients, in trauma patients in the pediatric population in the
neonatal intensive care unit, but not specifically for patients
with congenital heart disease. We have been collaborating
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with the developer of these tests, and I believe that she will
use these results to validate them for the screening methods. 
I do not have the answer for your second question about the
socioeconomic impact. This relates also to the fact that non-
white race came out as an independent risk factor. We cer-
tainly are going to further investigate that question, but it is
not an easy question to answer. 
The patients became eligible for these tests 2 or 3 months
after the operation. Therefore a number of patients fell out for
that reason. Ten families could not be traced at all, despite all of
our efforts, and 2 families refused collaboration in this study. 
With the present data set we were unable to find a specific
risk factor influencing the costs. However, the patients who
completed all 3 stages had lower initial costs. The inference
from that is that if the patient does well, especially at stage I
repair, the cost of these procedures can be reduced. I believe
the best way to save money is to reduce the circulatory arrest
time and improve cardiac performance after stage I. 
I believe that the patients who died after stage I repair had
much more severe ventricular dysfunction than other patients,
with much longer crossclamp times. The reasons for that are
unclear at present but may involve the coronary vessels,
which are very tiny at the base of the small ascending aorta,
and the postoperative relationship of those small coronary
vessels to the large neoaorta. I believe technical improve-
ments could lead to a substantial decrease in long-term costs. 
Appendix
The Dunnett procedure is used when the sole comparisons
of interest are of the several individual treatments against a
control group.
This multiple comparison procedure was therefore
employed to compare the IT CHQ data, that is, each group
mean versus the reference population. The calculated test sta-
tistics (Li) were compared to a table of critical values for
Dunnett’s criterion. 
The critical value from the Dunnett table for 3, 198 degrees
of freedom was 2.35. Because all sample sizes were not
equal, this value was further adjusted, as recommended by
Fleiss, by multiplying this value by 
1 + 0.07(1 – ni/no)
where ni = treatment sample size and no = control sample
size.
The adjusted critical value for all three treatments was
2.51. Therefore, all Li were compared to 2.51.
Because raw data were not available, P values could not be
generated; only whether the observable differences were sig-
nificant or not by comparing the Dunnett test statistics to the
critical value.
No additional adjustments (eg, Bonferroni) were made for
the 9 outcome variables measured. For these tests, alpha was
set at 0.05, 2-tailed.
Appendix Table I.  Test statistics (Li) for the Dunnett multiple comparisons procedure used in analyzing the IT
CHQ data (Table III), which were than compared to the critical value of 2.51
Stage N L1 L2 L3 L4
1 8 –0.60934 –0.17221 1.56363 –0.20755
2 11 –2.62351 –3.30654 –9.26783 –3.29388
3 8 –0.77642 –2.16981 3.07840 –0.36897
L5 L6 L7 L8 L9
1.95224 –1.10582 –9.2673 –2.53275 –0.19089
0.73468 –2.38493 –12.8936 –3.35548 –0.54276
0.41834 –1.10582 –7.1409 –1.95510 –0.22725
